BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3164269)

  • 1. A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
    Chisesi T; Capnist G; de Dominicis E; Dini E
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):681-4. PubMed ID: 3164269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients.
    Bastholt L; Dalmark M
    Cancer Treat Rep; 1987 May; 71(5):451-4. PubMed ID: 3471329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
    Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
    Ganzina F; Pacciarini MA; Di Pietro N
    Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial with oral idarubicin in advanced breast cancer.
    Lopez M; Di Lauro L; Papaldo P; Lazzaro B; Ganzina F; Di Pietro N
    Invest New Drugs; 1986; 4(1):39-42. PubMed ID: 3457780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
    Wander HE; Meyer D; Schuff-Werner P; Nagel GA
    Onkologie; 1986 Aug; 9(4):236-8. PubMed ID: 3531951
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II trial of idarubicin in patients with advanced lymphoma.
    Gillies H; Liang R; Rogers H; Harper P; Parapia L; Cox G; Johnson S
    Cancer Chemother Pharmacol; 1988; 21(3):261-4. PubMed ID: 3162850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma.
    Lopez M; Di Lauro L; Papaldo P; Ganzina F; Di Pietro N; Lazzaro B
    Cancer Treat Rep; 1986 Jul; 70(7):911-2. PubMed ID: 3459575
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I study of 4-demethoxydaunorubicin.
    Bonfante V; Ferrari L; Villani F; Bonadonna G
    Invest New Drugs; 1983; 1(2):161-8. PubMed ID: 6590530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.
    Smith DB; Howell A
    Eur J Cancer Clin Oncol; 1987 Apr; 23(4):391-4. PubMed ID: 3475204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial.
    Hochster HS; Green MD; Blum RH; Wernz JC; Speyer JL; Muggia FM
    Invest New Drugs; 1986; 4(3):275-8. PubMed ID: 3469171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study.
    Martoni A; Pacciarini MA; Pannuti F
    Drugs Exp Clin Res; 1985; 11(2):127-31. PubMed ID: 3915281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study.
    Bruzzone M; Chiara S; Falcone A; Graziani G; Conte PF; Rosso R
    Chemioterapia; 1987 Apr; 6(2):137-9. PubMed ID: 3474080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
    Stuart NS; Cullen MH; Priestman TJ; Blackledge GR; Tyrrell CJ
    Cancer Chemother Pharmacol; 1988; 21(4):351-4. PubMed ID: 3163529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A phase I trial of idarubicin by oral administration].
    Ogawa M; Kimura K; Taguchi T; Wakui A; Hattori M; Shimoyama T; Fujita H
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1896-900. PubMed ID: 3473981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New anthracycline analogs in advanced breast cancer.
    Bonfante V; Ferrari L; Brambilla C; Rossi A; Villani F; Crippa F; Valagussa P; Bonadonna G
    Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1379-85. PubMed ID: 3470179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary observations on intravenous idarubicin (4-demethoxydaunorubicin) in the chronic and accelerated phase of chronic myelogenous leukemia.
    Battista R; D'Emilio A; Vespignani M; Pacciarini MA; Dini E
    Tumori; 1986 Aug; 72(4):389-93. PubMed ID: 3464125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia.
    Hayat M; Hurteloup P; Parmentier C; Carde P; Pico JO; Schlumberger M; Chahine G; Kamioner D
    Invest New Drugs; 1984; 2(4):375-9. PubMed ID: 6595242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of idarubicin in advanced endometrial carcinoma.
    Hakes TB; Raymond V
    Cancer Treat Rep; 1987 May; 71(5):535-6. PubMed ID: 3471330
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma.
    Sumpter K; Powles RL; Raje N; Ramiah V; Kulkarni S; Treleaven J; Mainwaring PN
    Leuk Lymphoma; 1999 Nov; 35(5-6):593-7. PubMed ID: 10609797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.